Skip to Content
  • Title
    Deputy CEO; Vice Chair of the Executive Board; CEO, Healthcare; CEO Designate
  • Company
    Merck KGaA
  • Country
    Darmstadt, Germany

It’s been a big year for Garijo, who in September was announced as the next CEO of Merck KGaA—the Darmstadt, Germany–based pharma company with $19 billion in annual revenues and a market capitalization of $66.2 billion. That news followed her promotion to deputy CEO and vice chairman of the executive board in July and positions her to become just one of two women running a major pharmaceutical company when she takes over in May 2021. (Emma Walmsley, No. 1, on this list is the other.) While COVID-19 had a significant negative impact on the health care division Garijo has overseen for the past five years, with sales declining 10.6% to $1.77 billion in Q2, she played a key leadership role in a cross-divisional COVID-19 innovation task force that established a portfolio of about 50 potential projects, including vaccines, transmission control and virus detection measures, access to therapies, and predictive modeling.

Subscribe to The Broadsheet, our newsletter on the world’s most powerful women.

Personal Information

Previous Rank-
Newcomer?
yes